A hot lead on reducing infarct size.

The intracoronary hyperoxemic oxygen therapy study, designed to demonstrate the safety of supersaturated oxygen (SSO2 ) infused into the left main coronary after percutaneous coronary intervention for anterior ST-elevation myocardial infarction (STEMI), demonstrated a net adverse clinical event rate of 7.1%, lower than the Food and Drug Administration-set goal of 10.7%. SSO2 , which has reduced infarct size in clinical STEMI trials, might become an important strategy for treating anterior STEMIs. Larger postmarketing trials are needed to determine whether decreases in infarct size are observed in real-world populations, whether they translate into improved clinical outcomes, and whether modifications in technique can streamline the administration of SSO2 therapy.